Orion Oyj just dropped its Q2 2026 scorecard and the headline is clear. The pharma group reported basic earnings per share of €1 on revenue of €521.6m, solid figures for a single quarter in this sector. Yet the stock closed today at €95.95 after a strong run over the past 90 days of 18.53%. Short term optimism already sits in the price. The question for traders is whether that recent enthusiasm reflects the earnings gap between Orion’s current P/E of 22.9x and a discounted cash flow value of €218.01.
Like Orion Oyj’s earnings power but uneasy about paying 22.9x P/E after a sharp 18.53% run in 90 days? Compare this quarter with a curated list of solid balance sheet stocks in our list of solid balance sheet and fundamentals stocks (207 results).
Q2 2026 Earnings Summary
- Revenue (Q2 2026 vs. Q2 2025): €521.6m vs. €416.5m (top line higher year on year)
- Net Income (Q2 2026 vs. Q2 2025): €140.2m vs. €82.5m (profit level higher compared with the prior period)
- Basic EPS (Q2 2026 vs. Q2 2025): €1.00 vs. €0.59 (earnings per share higher than a year ago)
- R&D Pipeline (Q2 2026 vs. Q2 2025): Phase I: 3 vs. 1, Phase II: 8 vs. 4, Phase III: 6 vs. 5 (wider late stage and early stage development portfolio)
Tired of squinting at rows of earnings figures and R&D line items for Orion Oyj? Get a clean visual dashboard of the business, including its valuation picture, in the company report for Orion Oyj.
Orion Oyj Hits Key Oncology Execution Milestones
Bullish commentary hinges on Orion Oyj turning its oncology ambitions into concrete progress rather than just projections.
"Bullish analysts expect Orion Oyj to build on Nubeqa led oncology growth, expand its cancer pipeline around ODM‑212, and deepen its presence in high value hospital and biologics markets over time."
Recent numbers and updates give this view firmer footing. Q3 2026 net sales of €542m and operating profit of €210m show earnings leverage, as Nubeqa related income now represents about half of year to date revenue. ODM‑212 is running in Phase II basket and combination studies. ODM‑216, the first in house biologic, has entered Phase I. In addition, the pembrolizumab biosimilar deal and raised 2026 guidance indicate that hospital oncology and biologics are moving from plan to execution.
The price and this Narrative do not agree. → Uncover what this Narrative says Orion Oyj is actually worth.
Orion Oyj: Concentration Risks Still Largely Unresolved
Bearish analysts argue that Orion Oyj is loading too much earnings weight onto a single oncology pillar while margin risks build in the background.
"Although Nubeqa royalties and product sales now drive much of Orion Oyj’s earnings, the reliance on a single partnered asset means any slowdown in market sales or pricing pressure would feed directly into royalty income and leave revenue and operating profit exposed."
Q3 confirms this concentration rather than easing it. Nubeqa related income accounts for roughly half of year to date revenue and management again frames full year guidance uncertainty around that franchise. Tariff exposure is being addressed through new U.S. API sourcing, yet this mitigation is still in progress and not tested under a full year of U.S. duties.
Hunt Quiet Disconnects In Plain Sight
Orion Oyj now reports firm quarterly numbers that spark a clear valuation debate. The real opportunity is spotting stocks that could be undervalued before the market adjusts their pricing.
- Company 1 - 23% below our estimate - serves long funded defense programs ramping munitions, vehicles, electronics and space output on multi year contracts.
- Company 2 - 43% below our estimate - targets the shift to larger LED screens as venues, transport hubs and youth sports fields upgrade from static signage.
- Company 3 - 32% below our estimate - sells the AI hardware and software stack large data centre customers rely on for compute hungry workloads.
That is three of the list. See every one of the 195 undervalued companies on it →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com